CAESAREA, Israel , Nov. 19, 2024 /PRNewswire/ -- Epitomee Medical Ltd. ( TASE : EPIT ) announces that significant results from its RESET study on a novel oral hydrogel capsule for weight loss were presented at ObesityWeek® 2024 .
The prestigious event, organized by The Obesity Society (TOS) , took place from November 2-6, 2024 , in San Antonio, Texas . The oral presentation, delivered by Professor Jamy D. Ard MD of Wake Forest University School of Medicine, highlighted the results of a randomized, double-blind, placebo-controlled study assessing the safety and efficacy of the Epitomee® Capsule .
Professor Ard, an esteemed leader in obesity research and President of The Obesity Society, emphasized the potential impact of this innovative, drug-free capsule for weight loss. The Epitomee capsule works by expanding into a triangular shape in the stomach, enhancing satiety, reducing appetite and calorie intake through a non-pharmacological mechanism. Results of the RESET Study: Patients were randomized to Epitomee (n=138) or placebo (n=141).
The study demonstrated that both co-primary endpoints were successfully met. The RESET study demonstrated significantly better weight loss among the device group compared to the control group (P35% (P<0.0001).
~60% of the Epitomee group were found to be early responders, identified as those losing at least 2% of body weight at week 8 achieving an average of ~10% weight loss at week 24. Significant reductions of change from baseline in HOMA-IR.